SAM
ADMA icon

Smartleaf Asset Management’s ADMA Biologics ADMA Stock Holding History

Smartleaf Asset Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.37K Hold
881
– – ﹤0.01% 2501
2026
Q1 		$8.06K Sell
881
-3,032
-77% -$47.8K ﹤0.01% 2429
2025
Q4 		$71.8K Buy
3,913
+565
+17% +$9.52K ﹤0.01% 1367
2025
Q3 		$49.2K Buy
3,348
+230
+7% +$3.94K ﹤0.01% 1406
2025
Q2 		$56.6K Buy
3,118
+700
+29% +$14.3K 0.01% 1114
2025
Q1 		$49K Buy
2,418
+1,493
+161% +$25.8K ﹤0.01% 1157
2024
Q4 		$16.2K Buy
+925
New +$17.4K ﹤0.01% 1766

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Smartleaf Asset Management's ADMA Position: Q2 2026 in Review

Smartleaf Asset Management held its ADMA Biologics (ADMA) position steady in Q2 2026 at 881 shares worth $7.37K. The position accounts for ﹤0.01% of the portfolio, ranked #2501.

Smartleaf Asset Management first reported a position in ADMA in Q4 2024 and has held it in 7 quarters since. The position peaked at $71.8K in Q4 2025. 322 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Smartleaf Asset Management held 881 shares of ADMA Biologics worth $7.37K as of Q2 2026.
  • Smartleaf Asset Management left its ADMA Biologics share count unchanged in Q2 2026.
  • ADMA Biologics made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q2 2026, its #2501 holding.
  • Smartleaf Asset Management first reported a position in ADMA Biologics in Q4 2024 and has held it in 7 quarters since.
  • Smartleaf Asset Management's ADMA Biologics position peaked at $71.8K in Q4 2025.
  • 322 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Smartleaf Asset Management's 13F filing for Q2 2026, filed 12 Aug 2026.